Quality of life (QoL) is a relevant endpoint and a topic of growing interest by both scientific community and regulatory authorities. Our aim was to review QoL prevalence as an endpoint in cancer phase III trials published in major journals and to evaluate QoL reporting deficiencies in terms of underreporting and delay of publication.
Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016
Marandino, L;La Salvia, A;Sonetto, C;De Luca, E;Pignataro, D;Zichi, C;Di Stefano, R;Ghisoni, E;Lombardi, P;Mariniello, A;Reale, M;Trevisi, E;Leone, G;Muratori, L;Marcato, M;Bironzo, P;Novello, S;Aglietta, M;Scagliotti, G;Perrone, F;Di Maio, M
Co-last
2018-01-01
Abstract
Quality of life (QoL) is a relevant endpoint and a topic of growing interest by both scientific community and regulatory authorities. Our aim was to review QoL prevalence as an endpoint in cancer phase III trials published in major journals and to evaluate QoL reporting deficiencies in terms of underreporting and delay of publication.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
OP-ANNO180455 2288..2295.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
250.19 kB
Formato
Adobe PDF
|
250.19 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
